Veru (STU:FMW) Common Stock : €1.37 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Veru Common Stock?

Veru's quarterly common stock increased from Sep. 2023 (€0.88 Mil) to Dec. 2023 (€1.36 Mil) and increased from Dec. 2023 (€1.36 Mil) to Mar. 2024 (€1.37 Mil).

Veru's annual common stock increased from Sep. 2021 (€0.70 Mil) to Sep. 2022 (€0.84 Mil) and increased from Sep. 2022 (€0.84 Mil) to Sep. 2023 (€0.88 Mil).

Veru Common Stock Historical Data

The historical data trend for Veru's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Common Stock Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Common Stock

Get a 7-Day Free Trial

0.61

0.70

0.84

0.88

Veru Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.79	0.84	0.88	1.36	1.37

Veru Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Veru (STU:FMW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

VERU:USA FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines